Cell genomics

made easy

Services

We care for your cells

Stem Genomics provides specific services to assess the genetic integrity of stem cells. We offer a range of new tests that use droplet digital PCR and a panel of specific probes to detect most of the recurrent genetic abnormalities observed in stem cells. This innovation, called iCS-digital (in Culture Supernatant digital PCR), is rapid, robust, and cost-effective, and can be performed on cell culture supernatants.

iCS-digital TM PSC
The in Culture Supernatant-digital PCR (iCS-digital TM) PSC test detects more than 90% of recurrent genomic abnormalities in human pluripotent stem cells (hPSCs), i.e. human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

The gene Editing-digital PCR (Ed-digital) test directly informs on the presence and number of transgenes inserted in the genome of CRISPR-edited cells.

About

Stem Genomics

Stem Genomics develops a technology invented by Prof John De Vos and Dr Said Assou, researchers at the Institute for Regenerative Medicine & Biotherapy (IRMB), University of Montpellier, and co-founders of the company. Located at the heart of the University Hospital Centre of Montpellier, IRMB houses research groups working on basic stem cell research and on innovative applications for regenerative therapy, with the aim of facilitating the transfer from research to clinical applications. Stem Genomics is located at the IRMB Cyborg business incubator and works in close collaboration with IRMB researchers. Stem Genomics has emerged from a prestigious scientific environment.

References

They trust us

Reference Stem Genomics
Reference Stem Genomics
Reference Stem Genomics
Reference Stem Genomics
Reference Stem Genomics
Reference Stem Genomics
https://bioneer.dk/
Reference Stem Genomics
Reference Stem Genomics
Reference Stem Genomics
https://www.bcm.edu/research/advanced-technology-core-labs/lab-listing/human-stem-cell-core
Reference Stem Genomics
Reference Stem Genomics
Reference Stem Genomics
Reference Stem Genomics
Reference Stem Genomics
Reference Stem Genomics

Latest news

discover and share

The iCS-digital TM test is a straightforward method for screening human pluripotent stem cell (hPSC) clones after CRISPR gene editing
The iCS-digital TM test offers fast and reliable detection of the most common genomic abnormalities in CRISPR/Cas9-edited hPSCs By combining human pluripotent stem cells (hPSCs) and the CRISPR/Cas9 genome editing technology, new opportunities are created to study disease mechanisms, with enormous therapeutic potential. Despite the progress in genome engineering, the CRISPR gene editing process consists of major sequential and potentially stressful events, such as clonal expansion, FACS enrichment, drug selection, manual colony picking or stressful single-cell dissociation. By triggering selective pressures on cells, these procedures could favour the generation and selection of genetically abnormal hPSCs, and consequently render these cells unsuitable for further use. Therefore, efficient and rapid screening of CRISPR-modified hPSCs is essential before their use for research purposes or clinical applications. Discover the test and request a quote

iCS-digital: A method for monitoring hPSC genome integrity that detects more than 90% of recurrent genomic abnormalities. The test is rapid (2-3 days), convenient (full service), straightforward, and can be performed using cell culture supernatant. It is particularly suitable for the routine monitoring of cell lines in culture and for screening genetically stable clones (e.g., CRISPR-edited iPSC clones, patient-derived iPSC clones…).